Trial · NCT00633061
Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer
NCT00633061, Phase 2, Terminated, University of Texas Southwestern Medical Center; results first posted 2019-03-08
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer. Trials, record NCT00633061. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00633061
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Identification and Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis in Children With Cancer
- NCT number
- NCT00633061
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 136 participants, actual
- Lead sponsor
- University of Texas Southwestern Medical Center
- Conditions
- Childhood Cancer, Central Venous Catheters, Deep Vein Thrombosis, Catheter-related Infection, Catheter-related Occlusion
- Interventions
- Enoxaparin
- First posted
- 2008-03-11
- Last updated
- 2020-10-08
- Results first posted
- 2019-03-08
- Limitations and caveats
Study terminated early for lack of accrual on Arm B (randomized trial). No patient enrolled on Arm A (screening study) were eligible. Standard treatment of asymptomatic catheter-related DVT changed in 2010, favoring treatment with enoxaparin.
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Composite Endpoint for Arm B of the Study: Catheter Removal, Signs and Symptoms of DVT or PE, OR Bacteremia/Fungemia | 16 weeks | catheter removal, signs and symptoms of DVT or PE, OR bacteremia/fungemia |
| Secondary | Bleeding Complications Associated With Enoxaparin Therapy, Need for Additional Platelets | 6 weeks | Bleeding complications associated with enoxaparin therapy, need for additional platelets |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Composite Endpoint for Arm B of the Study: Catheter Removal, Signs and Symptoms of DVT or PE, OR Bacteremia/Fungemia | 16 weeks | No patient was enrolled on the randomized clinical trial (arm B) after being on the prospective screening trial (Arm A) | ||
| SECONDARY | Bleeding Complications Associated With Enoxaparin Therapy, Need for Additional Platelets | 6 weeks | Since no patient was enrolled on Arm B of this study, there is no analysis of bleeding. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow10
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | A-Prosepctive Screening for Asymptomatic DVT | 136 | |
| Overall Study | STARTED | B-Randomized Clinical Trail for Treatment | 0 | |
| Overall Study | Met Criteria for Imaging | A-Prosepctive Screening for Asymptomatic DVT | 25 | |
| Overall Study | Met Criteria for Imaging | B-Randomized Clinical Trail for Treatment | 0 | |
| Overall Study | Had Prior Thrombosis Identified | A-Prosepctive Screening for Asymptomatic DVT | 25 | |
| Overall Study | Had Prior Thrombosis Identified | B-Randomized Clinical Trail for Treatment | 0 | |
| Overall Study | COMPLETED | A-Prosepctive Screening for Asymptomatic DVT | 50 | |
| Overall Study | COMPLETED | B-Randomized Clinical Trail for Treatment | 0 | |
| Overall Study | NOT COMPLETED | A-Prosepctive Screening for Asymptomatic DVT | 86 | |
| Overall Study | NOT COMPLETED | B-Randomized Clinical Trail for Treatment | 0 |
Source ClinicalTrials.gov
Adverse events4
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Thrombosis | Vascular disorders | A-Prospective Screening for Asymptomatic Catheter-related DVT | 7 | 136 | 7 |
| serious | Thrombosis | Vascular disorders | B-Randomized Clinical Trial | 0 | 0 | |
| serious | removal of indwelling catheter for reasons other than end of therapy | Vascular disorders | A-Prospective Screening for Asymptomatic Catheter-related DVT | 9 | 136 | 9 |
| serious | removal of indwelling catheter for reasons other than end of therapy | Vascular disorders | B-Randomized Clinical Trial | 0 | 0 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | A-Prospective Screening for Asymptomatic Catheter-related DVT | 0 | 136 |
| Total, all-cause mortality | B-Randomized Clinical Trial | 0 | 0 |
| Total, other adverse events | A-Prospective Screening for Asymptomatic Catheter-related DVT | 0 | 136 |
| Total, other adverse events | B-Randomized Clinical Trial | 0 | 0 |
| Total, serious adverse events | A-Prospective Screening for Asymptomatic Catheter-related DVT | 16 | 136 |
| Total, serious adverse events | B-Randomized Clinical Trial | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| K23HL084097 | Treatment of Clinically Silent Catheter-Related Deep Vein Thrombosis | JOURNEYCAKE, JANNA M | UT SOUTHWESTERN MEDICAL CENTER | NATIONAL HEART, LUNG, AND BLOOD INSTITUTE | 2006 to 2010 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00633061
GET https://conductscience.org/api/trials/v1/NCT00633061/registered